Daniel Brownell

Senior Director - Research & Development AOBiome Therapeutics

Seminars

Tuesday 10th November 2026
Demonstrating Clinically Credible Evidence and Manufacturing Feasibility to Unlock Investment for Microbiome Therapeutics
3:30 pm
  • Establishing clear pathways to regulatory approval through comparisons to existing products and demonstrated improvements in efficacy and safety to satisfy investor due diligence
  • Addressing unmet therapeutic needs while showing likelihood of success to build investor confidence in achieving viable returns on capital deployed
  • Communicating manufacturing scalability and cost of goods considerations for complex live bacterial production systems to address investor concerns about production feasibility
Daniel Brownell, AOBiome - Expert Speaker at the 11th Microbiome Movement USA Summit